Brugada syndrome risk factors: Difference between revisions
Jump to navigation
Jump to search
| Line 20: | Line 20: | ||
*[[α-adrenergic agonists]] | *[[α-adrenergic agonists]] | ||
*[[β-adrenergic blockers]] | *[[β-adrenergic blockers]] | ||
*[[Tetracyclic | *[[Tetracyclic antidepressants]] | ||
*A combination of [[glucose]] and [[insulin]] | |||
==Risk Statification== | ==Risk Statification== | ||
Revision as of 01:32, 14 October 2012
|
Brugada syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Brugada syndrome risk factors On the Web |
|
American Roentgen Ray Society Images of Brugada syndrome risk factors |
|
Risk calculators and risk factors for Brugada syndrome risk factors |
Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Risk Factors: Agents and Scenarios that Provoke the Brugada Syndrome Pattern
The electrocardiographic findings of Brugada syndrome are often concealed, but can be unmasked or modulated by a number of drugs and pathophysiological states including:
- Ajmaline (a diagnostic test agent)
- Cocaine
- Fever
- Flecainide (a diagnostic test agent)
- In large studies, a family history of sudden cardiac death among patients with Brugada syndrome does not appear to be a risk factor for sudden cardiac death in siblings.
- Procainamide (a diagnostic test agent)
- Propranolol intoxication
- Sodium channel blockers (a diagnostic test agent)
- Tricyclic antidepressants
- Vagotonic agents that mimic sleep
- α-adrenergic agonists
- β-adrenergic blockers
- Tetracyclic antidepressants
- A combination of glucose and insulin
Risk Statification
- Patients with syncope and an abnormal Type 1 ECG are at higher risk
- Asymptomatic patients at risk can be identified
- Presence of spontaneous Type 1 ST-segment elevation
- Characteristics of the S wave
- Presence of late potentials
- Inducibility of VT/VF using PES is controversial as a risk factor.